atorvastatin has been researched along with sertraline in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Asch, SM; Escarce, JJ; Lewis, JH; Muñoz, JA; Rosen, MR; Schonlau, M; Yang, H | 1 |
| Brain, RA; Hanson, ML; Johnson, DJ; Lam, MW; Mabury, SA; Richards, SM; Sanderson, H; Sibley, PK; Solomon, KR; Young, C | 1 |
| Leighton, JA; Luckritz, TC; Patel, BM; Rady, MY; Wells, CD; Zornik, JM | 1 |
| Hanson, ML; Kelly, SE; Richards, SM | 1 |
| Feldmann, J; Jurcsik, A; Kopcsányi, H; Péch, Z | 1 |
1 review(s) available for atorvastatin and sertraline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for atorvastatin and sertraline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antidepressive Agents; Atorvastatin; California; Cost Savings; Drug Costs; Drug Prescriptions; Health Expenditures; Heptanoic Acids; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Lactones; Medicare; Prescription Fees; Pyrroles; Sertraline; Sulfones; United States | 2002 |
Microcosm evaluation of the effects of an eight pharmaceutical mixture to the aquatic macrophytes Lemna gibba and Myriophyllum sibiricum.
Topics: Acetaminophen; Analysis of Variance; Atorvastatin; Biological Assay; Biomass; Caffeine; Carbamazepine; Complex Mixtures; Dose-Response Relationship, Drug; Heptanoic Acids; Heterocyclic Compounds; Levofloxacin; Magnoliopsida; Ofloxacin; Pharmaceutical Solutions; Pyrroles; Sertraline; Sulfamethoxazole; Toxicity Tests; Trimethoprim; Water Pollutants, Chemical | 2004 |
Bezoar formation requiring endoscopic removal after intentional overdose of extended-release nifedipine.
Topics: Anticholesteremic Agents; Antidepressive Agents; Atorvastatin; Bezoars; Calcium Channel Blockers; Cyclohexanols; Delayed-Action Preparations; Drug Overdose; Endoscopy, Digestive System; Fatal Outcome; Female; Heptanoic Acids; Humans; Middle Aged; Nifedipine; Pyrroles; Radiography; Sertraline; Stomach; Venlafaxine Hydrochloride | 2006 |
Zooplankton chitobiase activity as an endpoint of pharmaceutical effect.
Topics: Acetylglucosaminidase; Animals; Atorvastatin; Biological Assay; Daphnia; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Environmental Monitoring; Fluoxetine; Heptanoic Acids; Lethal Dose 50; Lovastatin; Pyrroles; Sertraline; Water Pollutants, Chemical; Xenobiotics; Zooplankton | 2008 |
[Difficulties in detecting the causative agent of an adverse drug reaction in a complicated case].
Topics: Administration, Cutaneous; Administration, Oral; Anticonvulsants; Antidepressive Agents; Atorvastatin; Azabicyclo Compounds; Drug Eruptions; Female; Heptanoic Acids; Humans; Lamotrigine; Middle Aged; Piperazines; Pyrroles; Risperidone; Sertraline; Skin Tests; Triazines | 2008 |